The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What need
Is there some
CTSFO.. thank you kindly sir for your time and research .. This share really does seem like a hidden Gem , and quite clearly 12 p is the lowest price anyone will ever get in on now , could be too late if the nxt RNS land with news .. this will fly ...
Totally agree Jimnzi. Very sorry for focusing on the heart valve development. RUA so much more than a one trick pony. It’s about time the market realised this.
And finally, latest RNS indicates profitability in H2 2024, so brokers note out of date. And when profitable, earnings multiples kick in. There’s more than the heart valve material side
Tiger, finally this might be of use. This is the most recent broker’s note I can find. Issued before the 20th December 2023 RNS re the heart valve testing, and the recent business update RNS. So the £62,000,000 (approximately £1.00 a share) value they put on the company is a marked undervaluation imo. They mention something similar themselves.
https://wp-aortech-2020.s3.eu-west-2.amazonaws.com/media/2023/12/20155651/RUA-Life-Sciences-plc-18-December-2023.pdf
Yet another review article on polymeric heart valves. Gives a good overview of the present state of development.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034107/
Tiger, always very difficult to predict sp movements, especially on AIM. So many shares seem to need constant support from RNSs to maintain a fair value. People get bored and move into the next shiny unicorn.
The fundamentals of RUA are sound. The BoD is achieving its present objectives of increasing growth and profitability, whilst having a £4,000,000 buffer in the bank. All excellent.
What I can’t find is a breakdown of the manufacturing cost of an artificial heart valve. How much would a manufacturer pay to use Elast Eon per valve produced? Elast Eon is already in use in implantable devices, so it’s cost effective against other polymers. Not sure a premium can be charged for its use just because it’s going into the heart. Or I’m wrong here, and a premium is payable because of additional testing and certification required.
Thank you CTSFO ...
so basically anything can happen anytime , one rns could change everything ...for now I see the price of SP holding tight .. cant see t going below 11p only up .. your thought s ?
Hi all. IntraVnus, that’s very helpful - thank you 🙏
Tiger, I’m a newbie here as well. A new heart valve will need a minimum of 6 months bench top trials before any useful information will be released. But this is being done by a global heart valve manufacturer. They won’t necessarily update the market. RUA might be tied into a confidentiality agreement with the manufacturer, though market sensitive information might still need to be released as per AIM rules.
What we don’t know is how the manufacturer will test the RUA sample for. Then design or incorporate it into a new trial heart valve. Only then will the 6 month trial commence. So an update might not be imminent.
The sp dropped following dilutional funding and change in product development pathway - if I read it right. But this is also AIM, a market that is struggling.
What we can’t ignore is the potential for a takeover / M&A. If enough global heart valve manufacturers trial the RUA product, and realise its the ‘holy grail’, will we see a bidding war?
Excuse the blatant ramping!
Important distinction with RUA’s polymeric material is that the polymer is interwoven into fine fabric. The other polymeric HV competitors (read Foldax) created theirs from pure polymer which doesn’t have the amazing properties that RUA’s composite has exhibited in their own tests.
This was an accidental finding to some extent because it came out of the work done to create the surgical textile grafts sealed with Elasteon polymer that are awaiting a clinical trial.
This is the reason they are saying the testing is so good in terms of existing valve materials. I don’t believe that anyone has a lead here but of course it’s all about whether the major looking at the material thinks it has legs in forming heart valves in their own designs using this new material rather than animal tissue. I hope that RUA’s management has been able to make the case adequately.
Hi CTSFO
Firstly thank you for your informative response and time ...
I have been researching this stock and their potential which is huge , hence i cant understand why we are quite low in price presently ...
Now they said in Dec that it would take 6 months to trail and test the heart valve , which would mean that anytime now we should have confirmation of results ???
Now should the results be positive and the director being ex FDA .. should the SP fly and if so what can see be the outcome ??
Would appreciate your intel on the above ..
many thanks in advance
Tiger “Is this good for us?” Good question! I think it is. Obviously RUA isn’t the only polymer producer with an eye on the biological implant market. They’re playing catch up to a certain extent with others already more established in this part of the medical devices industry.
But if they have developed a polyurethane with the ideal properties of prolonged life expectancy and no side effects ( thrombus, calcification, etc) then I think we’re onto a winner.
“ RUA Structural Heart has the opportunity to transform the global treatment of heart disease by delivering a synthetic heart valve that will be durable, so reducing the need for future replacement, and should not require lifelong drug treatment. As well as these clinical advantages, the manufacturing costs of a synthetic valve are expected to be considerably less than those of current valve technology making this a potentially disruptive advance in heart valve surgery.”
If other polymers match the life expectancy and safety profiles of the RUA product, manufacturing cost will determine which plastic is used. Simple economics. It looks like a polyurethane is easier and cheaper to use as a PHV base material. This is good for us.
Also worth remembering the bench top PHV tests RUA have been doing will still be ongoing. So they will be able to update the market with the results of this. Way beyond the 400,000,000 cycles - if memory serves - expected as part of the standard trial process for a new PHV.
It’s an academic paper on the possible future.
Ctsfo is that goo for us ? new anytime now I believe ...
Polymeric Heart Valves will replace mechanical and biological replacements:
https://www.mdpi.com/1422-0067/24/4/3963
Many thanks Intra. Modest holdings based on much higher historic prices. Still would be good to see them exploiting current price if permitted
And no regulatory body involved - FDA - is a massive tick - billions $ cos have vanished with the FDA process [and the ages it takes]
The material is easy if not time consuming to test - its every single permutation of heart actions -20-300 beats per minute , the destruction test [pressure when tears] and enhanced degradation.
Its basically the same as testing an engine - which takes about 6 months [
They are not waiting on a valve to be approved (no regulatory body involved). They have a material being tested by a major heart valve manufacturer. If they like it they might go for a licensing deal. Being connected to a major would be the driver of share price, not the amount of the licensing deal.
Https://wp-aortech-2020.s3.eu-west-2.amazonaws.com/media/2023/07/28115440/NOV8-100035_RUA-Annual-Report-final.pdf
Page 37 (options) Page 38 (shares held)
Me to .. the RNS was in December .. 6 months required , so we are nearly there .. if the get approval of valve which is more than likely ... omg .. i just dont get why this is not moving in sp ... now
Offered 11.77 for whole holding so as a certain Mr Hogarth said in 2016 “something is cooking inside”
Now I’m getting just as impatient as anyone else lol.
Other than Bill there seems scant share ownership amongst board members. Anyone know about options or other incentives? I would like to see some insider buying unless in a closed period.
Much better now Zinc sell at mid price 11.75p and 11.88p to buy strongest for a while
11.57 to sell 11.72 to buy
Definitely in an uptrend and a few meaningful buys over last 24 hours
Premiums wanted for 50k for example